Braak H, Braak E. Neuropathological stageing of Alzheimer-related changes. Acta Neuropathol. 1991;82:239–59 Springer-Verlag.

Article  CAS  PubMed  Google Scholar 

Hyman BT, Phelps CH, Beach TG, Bigio EH, Cairns NJ, Carrillo MC, et al. National Institute on Aging–Alzheimer’s Association guidelines for the neuropathologic assessment of Alzheimer’s disease. Alzheimer’s Dement. 2012;8:1–13.

Article  Google Scholar 

Zetterberg H. Biofluid-based biomarkers for Alzheimer’s disease–related pathologies: An update and synthesis of the literature. Alzheimer’s Dement. 2022;18:1687.

Article  Google Scholar 

Lombardi G, Crescioli G, Cavedo E, Lucenteforte E, Casazza G, Bellatorre AG, et al. Structural magnetic resonance imaging for the early diagnosis of dementia due to Alzheimer’s disease in people with mild cognitive impairment. Cochrane database Syst Rev. 2020;3:CD009628.

PubMed  Google Scholar 

Bao W, Xie F, Zuo C, Guan Y, Huang YH. PET neuroimaging of Alzheimer’s disease: radiotracers and their utility in clinical research. Front Aging Neurosci. 2021;13:624330.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Cassinelli Petersen G, Roytman M, Chiang GC, Li Y, Gordon ML, Franceschi AM. Overview of tau PET molecular imaging. Curr Opin Neurol. 2022;35:230–9.

Article  PubMed  Google Scholar 

Villemagne VL, Fodero-Tavoletti MT, Masters CL, Rowe CC. Tau imaging: early progress and future directions. Lancet Neurol. 2015;14:114–24.

Article  PubMed  Google Scholar 

Mathis CA, Lopresti BJ, Ikonomovic MD, Klunk WE. Small-molecule PET Tracers for Imaging Proteinopathies. Semin Nucl Med. 2017;47:553–75.

Article  PubMed  PubMed Central  Google Scholar 

Schöll M, Lockhart SN, Schonhaut DR, O’Neil JP, Janabi M, Ossenkoppele R, et al. PET imaging of Tau deposition in the aging human brain. Neuron. 2016;89:971–82.

Article  PubMed  PubMed Central  Google Scholar 

Jack CR, Wiste HJ, Schwarz CG, Lowe VJ, Senjem ML, Vemuri P, et al. Longitudinal tau PET in ageing and Alzheimer’s disease. Brain. 2018;141:1517–28.

Article  PubMed  PubMed Central  Google Scholar 

Leuzy A, Smith R, Cullen NC, Strandberg O, Vogel JW, Binette AP, et al. Biomarker-based prediction of longitudinal tau positron emission tomography in Alzheimer disease. JAMA Neurol. 2021. Available from: https://jamanetwork.com/journals/jamaneurology/fullarticle/2787209.

Ossenkoppele R, Pichet Binette A, Groot C, Smith R, Strandberg O, Palmqvist S, et al. Amyloid and tau PET-positive cognitively unimpaired individuals are at high risk for future cognitive decline. Nat Med. 2022;28:2381–7.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Mattsson N, Schöll M, Strandberg O, Smith R, Palmqvist S, Insel PS, et al. 18F-AV-1451 and CSF T-tau and P-tau as biomarkers in Alzheimer’s disease. EMBO Mol Med. 2017;9:1212–23.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Bucci M, Chiotis K, Nordberg A. Alzheimer’s disease profiled by fluid and imaging markers: tau PET best predicts cognitive decline. Mol Psychiatry. 2021;26:5888–98.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Meyer PF, Pichet Binette A, Gonneaud J, Breitner JCS, Villeneuve S. Characterization of Alzheimer disease biomarker discrepancies using cerebrospinal fluid phosphorylated Tau and AV1451 positron emission tomography. JAMA Neurol. 2020;77:508–16.

Article  PubMed  PubMed Central  Google Scholar 

Jie CVML, Treyer V, Schibli R, Mu L. Tauvid™: The first FDA-approved PET tracer for imaging Tau pathology in Alzheimer’s disease. Pharmaceuticals (Basel). 2021;14:1–12.

Article  Google Scholar 

Tian M, Civelek AC, Carrio I, Watanabe Y, Kang KW, Murakami K, et al. International consensus on the use of tau PET imaging agent 18F-flortaucipir in Alzheimer’s disease. Eur J Nucl Med Mol Imaging. 2022;49:895–904.

Article  PubMed  PubMed Central  Google Scholar 

Marquié M, Normandin MD, Vanderburg CR, Costantino IM, Bien EA, Rycyna LG, et al. Validating novel tau positron emission tomography tracer [F-18]-AV-1451 (T807) on postmortem brain tissue. Ann Neurol. 2015;78:787.

Article  PubMed  PubMed Central  Google Scholar 

Lemoine L, Leuzy A, Chiotis K, Rodriguez-Vieitez E, Nordberg A. Tau positron emission tomography imaging in tauopathies: the added hurdle of off-target binding. Alzheimer’s Dement (Amsterdam, Netherlands). 2018;10:232–6.

Google Scholar 

Drake LR, Pham JM, Desmond TJ, Mossine AV, Lee SJ, Kilbourn MR, et al. Identification of AV-1451 as a weak, nonselective inhibitor of monoamine oxidase. ACS Chem Neurosci. 2019;10:3839–46 Available from: https://pubs.acs.org/doi/10.1021/acschemneuro.9b00326.

Article  CAS  PubMed  Google Scholar 

Leuzy A, Smith R, Ossenkoppele R, Santillo A, Borroni E, Klein G, et al. Diagnostic performance of RO948 F 18 tau positron emission tomography in the differentiation of alzheimer disease from other neurodegenerative disorders. JAMA Neurol. 2020;77:955–65.

Article  PubMed  Google Scholar 

Mueller A, Bullich S, Barret O, Madonia J, Berndt M, Papin C, et al. Tau PET imaging with 18F-PI-2620 in patients with Alzheimer disease and healthy controls: a first-in-humans study. J Nucl Med. 2020;61:911–9.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Kroth H, Oden F, Molette J, Schieferstein H, Capotosti F, Mueller A, et al. Discovery and preclinical characterization of [18F]PI-2620, a next-generation tau PET tracer for the assessment of tau pathology in Alzheimer’s disease and other tauopathies. Eur J Nucl Med Mol Imaging. 2019;46:2178–89.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Kroth H, Oden F, Molette J, Schieferstein H, Gabellieri E, Mueller A, et al. PI-2620 lead optimization highlights the importance of off-target assays to develop a PET tracer for the detection of pathological aggregated Tau in Alzheimer’s disease and other tauopathies. J Med Chem. 2021;64:12808–30.

Article  CAS  PubMed  Google Scholar 

Honer M, Gobbi L, Knust H, Kuwabara H, Muri D, Koerner M, et al. Preclinical evaluation of 18F-RO6958948, 11C-RO6931643, and 11C-RO6924963 as novel PET radiotracers for imaging Tau aggregates in Alzheimer disease. J Nucl Med. 2018;59:675–81.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Oliveira Hauer K, Pawlik D, Leuzy A, Janelidze S, Hall S, Hansson O, et al. Performance of [18F]RO948 PET, MRI and CSF neurofilament light in the differential diagnosis of progressive supranuclear palsy. Park Relat Disord. 2023;106:105226. https://doi.org/10.1016/j.parkreldis.2022.11.018.

Article  CAS  Google Scholar 

Klunk WE, Koeppe RA, Price JC, Benzinger TL, Devous MD, Jagust WJ, et al. The Centiloid project: Standardizing quantitative amyloid plaque estimation by PET. Alzheimer’s Dement. 2015;11:1–15.e4.

Article  Google Scholar 

Leuzy A, Raket LL, Villemagne VL, Klein G, Tonietto M, Olafson E, et al. Harmonizing tau positron emission tomography in Alzheimer’s disease: the CenTauR scale and the joint propagation model. Alzheimers Dement. 2024. Available from: https://alz-journals.onlinelibrary.wiley.com/doi/10.1002/alz.13908.

Rodriguez-Gomez O, Sanabria A, Perez-Cordon A, Sanchez-Ruiz D, Abdelnour C, Valero S, et al. FACEHBI: a prospective study of risk factors, biomarkers and cognition in a cohort of individuals with subjective cognitive decline. Study rationale and research protocols. J Prev Alzheimer’s Dis. 2017;4:100–8.

CAS  Google Scholar 

Pérez-Cordón A, Monté-Rubio G, Sanabria A, Rodriguez-Gomez O, Valero S, Abdelnour C, et al. Subtle executive deficits are associated with higher brain amyloid burden and lower cortical volume in subjective cognitive decline: the FACEHBI cohort. Sci Rep. 2020;10:17721.

Article  PubMed  PubMed Central  Google Scholar 

Muñoz N, Gomà-I-Freixanet M, Valero S, Rodríguez-Gómez O, Sanabria A, Pérez-Cordón A, et al. Personality factors and subjective cognitive decline: the FACEHBI cohort. Behav Neurol. 2020;2020:5232184.

Article  PubMed  PubMed Central  Google Scholar 

Sanabria A, Alegret M, Rodriguez-Gomez O, Valero S, Sotolongo-Grau O, Monté-Rubio G, et al. The Spanish version of Face-Name Associative Memory Exam (S-FNAME) performance is related to amyloid burden in subjective cognitive decline. Sci Rep. 2018;8:3828.

Article  PubMed  PubMed Central  Google Scholar 

De Rojas I, Romero J, Rodríguez-Gomez O, Pesini P, Sanabria A, Pérez-Cordon A, et al. Correlations between plasma and PET beta-amyloid levels in individuals with subjective cognitive decline: the Fundació ACE Healthy Brain Initiative (FACEHBI) 11 medical and health sciences 1109 neurosciences. Alzheimer’s Res Ther. 2018;10:1.